List of Tavneos drug patents

Tavneos is owned by Chemocentryx.

Tavneos contains Avacopan.

Tavneos has a total of 2 drug patents out of which 0 drug patents have expired.

Tavneos was authorised for market use on 07 October, 2021.

Tavneos is available in capsule;oral dosage forms.

Drug patent challenges can be filed against Tavneos from October, 2025.

The generics of Tavneos are possible to be released after 03 February, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8906938 CHEMOCENTRYX C5aR antagonists
Dec, 2029

(6 years from now)

US8445515 CHEMOCENTRYX C5aR antagonists
Feb, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 7, 2028
New Chemical Entity Exclusivity (NCE) Oct 7, 2026

Drugs and Companies using AVACOPAN ingredient

NCE-1 date: October, 2025

Market Authorisation Date: 07 October, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in